Retatrutide: The Triple Agonist Rewriting Weight Loss Numbers

Last updated: April 2026. We refresh this article every 90 days as trial data evolves.

You've probably heard of Ozempic and Mounjaro. You might even know that Wegovy gets people to lose 15% of their body weight and that tirzepatide pushed that number to 22%. Those felt like big leaps. And now there's a drug that's making those numbers look modest.

Retatrutide, a triple agonist being developed by Eli Lilly, delivered 28.7% average body weight reduction in its TRIUMPH Phase 3 trial at 68 weeks. That's not a rounding error. At 200 pounds to start, that's 57 pounds. At 250 pounds, it's 72 pounds. Those are bariatric surgery numbers. Coming from a weekly injection.

But here's what you actually need to know: it isn't FDA-approved yet, there's no compounding pathway, and the earliest realistic approval date is 2027. If someone is selling you "retatrutide" right now through a telehealth clinic or peptide vendor, they're not selling you what the trials used. The risks of unverified sources are real.

This article covers the science, the real-world data, what the side effects actually look like, how it compares to tirzepatide and semaglutide, and what your options are right now if you're looking for physician-guided metabolic support.

---

What Is Retatrutide?

Retatrutide (also called LY3437943) is an investigational drug developed by Eli Lilly that activates three hormone receptors simultaneously: GLP-1, GIP, and glucagon. No approved weight loss drug currently targets all three at once. That's what makes it different — and why the weight loss numbers it produces have gotten the attention of every obesity researcher in the field.

To understand why three receptors matter, it helps to understand what each one does.

GLP-1 is the target of semaglutide (Ozempic, Wegovy). Activate this receptor and you get slower stomach emptying, reduced appetite, and better insulin response. That's the engine behind Ozempic's 15% weight loss.

GIP is the second receptor tirzepatide adds on top of GLP-1. It boosts insulin response further and, uniquely, appears to improve how fat tissue handles incoming calories, which is part of why tirzepatide outperforms semaglutide on weight loss (Jastreboff et al., 2022).

Glucagon is the new addition that separates retatrutide from everything that came before. Glucagon receptor activation increases energy expenditure and drives fat oxidation in the liver. Basically, it keeps your metabolic rate from crashing while you're losing weight — the same problem that causes plateaus on other GLP-1 medications (Barton et al., 2023). This is the piece of the puzzle that likely explains why retatrutide produces weight loss numbers that no other medication has matched.

Dr. Brad Stanfield, MD, who has reviewed the trial data publicly, called the TRIUMPH Phase 3 result "blowing my mind" and noted the 28.7% loss came with "profound relief from pain caused by knee arthritis." That's not marketing copy. That's a physician reacting to data he wasn't expecting.

---

How Much Weight Do People Actually Lose on Retatrutide?

The short answer: more than any other approved or investigational GLP-1 drug. In Phase 2 trials, participants lost up to 24.2% of body weight at 48 weeks. In the most recent Phase 3 data, that climbed to 28.7% at 68 weeks.

The landmark Phase 2 trial, published in the New England Journal of Medicine (Jastreboff et al., 2023), enrolled 338 adults with obesity or overweight without diabetes. At the highest dose of 12 mg weekly, mean body weight reduction hit 24.2% at 48 weeks. About 86% of participants on that dose lost at least 15% of their body weight.

Put that in human terms: if you started at 220 pounds, you'd end the trial at about 167 pounds. If you started at 275, you'd be around 210. Those are real transformations, not incremental improvements.

Then the TRIUMPH Phase 3 results landed. Participants receiving 12 mg retatrutide over 68 weeks averaged 28.7% body weight reduction — an average of 71.2 pounds lost (Lilly, 2025, NCT05882045). That's not just the best number any drug has produced in an obesity trial. It eclipses what many people lose from Roux-en-Y gastric bypass surgery in the same timeframe.

For comparison, here's how the numbers stack up across the GLP-1 class at their highest approved or trial doses:

Drug	Receptors	Study Duration	Mean Weight Loss
Semaglutide 2.4 mg (Wegovy)	GLP-1	68 weeks	~15%
Tirzepatide 15 mg (Zepbound)	GLP-1 + GIP	72 weeks	~22.5%
Retatrutide 12 mg	GLP-1 + GIP + Glucagon	48 weeks (Phase 2)	24.2%
Retatrutide 12 mg	GLP-1 + GIP + Glucagon	68 weeks (Phase 3)	28.7%

The Lancet Regional Health put it plainly: "The GLP-1R/GIPR/GcgR triple-agonist retatrutide achieves similar body weight loss (~25%) in just two-thirds of the time [compared to tirzepatide at 72 weeks], potentially surpassing the efficacy of Roux-en-Y gastric bypass" (Novikoff et al., 2024).

Ben Bikman, PhD, who researches metabolic disease and has analyzed the trial data, explained the glucagon contribution this way: "The glucagon component is contributing to this by maintaining energy expenditure and fat burning in a way that GLP-1 alone does not appear to achieve." That metabolic rate preservation is significant. It's what helps some people keep losing even past the point where GLP-1 drugs typically plateau.

---

How Does Retatrutide Work — The Mechanism

The reason three receptors produce better results than one or two isn't just additive math. There are synergistic effects between the pathways that change how your body responds to caloric restriction.

GLP-1 activation slows gastric emptying and reduces appetite. You feel full faster and stay fuller longer. It also improves insulin secretion after meals, so blood sugar stays steadier. This is the mechanism you already know from Ozempic.

GIP activation amplifies the insulin response further. But the interesting piece is what it does in fat tissue. GIP signaling improves blood flow to adipose tissue and influences how fat cells respond to incoming calories (Caruso et al., 2024). In people with obesity, this pathway is often dysregulated, and fat cells become resistant to insulin's normal signals. GIP agonism appears to partially restore that sensitivity.

Glucagon receptor agonism does something neither GLP-1 nor GIP can do on their own: it pushes energy expenditure up. Normally when you're in a caloric deficit, your body compensates by burning fewer calories at rest. It's a survival adaptation that evolution built in. The glucagon component appears to blunt this response, keeping thermogenesis running even as weight drops (Jakubowska et al., 2024).

The structural pharmacology is also notable. Li et al. (2024) published cryo-EM data showing exactly how retatrutide docks with all three receptors (GLP-1R, GIPR, and GCGR) simultaneously. The binding mechanism is what allows one molecule to activate all three pathways without losing potency at any of them. This was the key engineering challenge Eli Lilly solved.

Urva et al. (2023) found that retatrutide delays gastric emptying comparably to other GLP-1 medications, which contributes to fullness and post-meal glucose control. The half-life of approximately 6 days supports once-weekly dosing, the same injection schedule as tirzepatide and semaglutide.

---

Retatrutide vs Tirzepatide: The Real Comparison

Since tirzepatide (Mounjaro, Zepbound) is currently the most effective approved weight loss medication, this is the comparison most people want to know. There's actually a Phase 3 trial running right now that directly compares them head-to-head (NCT06662383, 800 participants, 89-week duration). Results aren't published yet, but the Phase 2 data and mechanistic differences tell a clear story.

Weight loss: Retatrutide 24.2% (Phase 2, 48 weeks) vs tirzepatide 22.5% (SURMOUNT-1, 72 weeks). That's a larger loss in less time. The Phase 3 data for retatrutide pushes the gap wider at 28.7%.

Mechanism: Tirzepatide adds GIP to GLP-1. Retatrutide adds GIP plus glucagon. The glucagon component is the variable. It's what appears to drive superior weight loss by maintaining metabolic rate, which is where tirzepatide (despite its dual action) still runs into the plateau problem.

Liver disease: The comparison here is striking. In a Phase 2b NASH trial, 86% of patients on retatrutide 8 mg achieved ≥50% reduction in liver fat at 48 weeks, and 73% achieved NASH resolution without worsening fibrosis (Ciardullo et al., 2024). For reference, the tirzepatide NASH trial presented at EASL 2023 showed 74% and 62% respectively. Both are impressive. Retatrutide's numbers are meaningfully better.

Availability: Tirzepatide is FDA-approved for weight management (Zepbound), available through licensed prescribers, and has an established dosing protocol. Retatrutide is still investigational. This is the critical practical difference: you can start tirzepatide with a physician today. Retatrutide, you cannot.

Side effects: Similar profile across both. More on this below.

Looking for a full breakdown of how GLP-1 medications compare across the class? Read our guide on GLP-1 Medications Compared.

---

Retatrutide Side Effects: What the Trials Actually Showed

The side effect profile is consistent with what the GLP-1 class produces: mostly gastrointestinal, mostly during dose escalation, mostly manageable with slow titration.

In the Phase 2 NEJM trial, the most frequent adverse events were nausea, diarrhea, vomiting, and constipation. In the 12 mg group, 19% of participants discontinued due to adverse events, compared to 2% in the placebo group (Jastreboff et al., 2023). That discontinuation rate is worth noting. It's higher than what's been reported with tirzepatide.

Nausea was the most reported symptom, affecting roughly half of participants in the highest dose groups during titration. Most cases were mild to moderate and decreased over time. This is the standard GLP-1 pattern: the side effects typically peak during escalation and improve at steady state.

A few findings that are specific to retatrutide and worth knowing about:

Heart rate increase. Retatrutide raised resting heart rate by up to 6.7 beats per minute on average (Doggrell, 2023). This is a class effect of GLP-1 drugs, but the magnitude with retatrutide may be slightly higher than with tirzepatide. For most people this is clinically insignificant. If you have a cardiac history, this is something your physician should evaluate.

Injection site reactions. Subcutaneous injection site redness and discomfort were reported, consistent with other injectable GLP-1s.

WADA status. Retatrutide is prohibited in competitive sports under WADA guidelines. If you compete in tested sports (Olympic, professional, or otherwise), this is not an option, period. It falls under metabolic modulators prohibited in and out of competition.

The FAERS adverse event database shows reports linked to GLP-1 class medications broadly. For retatrutide specifically, the Phase 3 cardiovascular outcomes trial (NCT05882045, 1,800 participants) will be the definitive safety dataset, with results expected before any FDA submission.

The key context Drucker (2024) provides in his Diabetes Care review is relevant here: the GLP-1 class has now accumulated years of safety data across millions of patients for semaglutide and tirzepatide. Retatrutide's structural similarity to those drugs is a reasonable basis for assuming comparable safety, but it isn't confirmed until Phase 3 safety data is fully analyzed.

Want more detail on what GLP-1 side effects look like in practice? Our article on Ozempic Side Effects covers the class-level patterns in depth.

---

What Retatrutide Does Beyond Weight Loss

Weight loss is the headline, but the downstream metabolic effects are what make this drug potentially transformative for people with multiple interacting conditions.

Type 2 diabetes. Phase 1b data showed retatrutide reduced HbA1c and body weight vs placebo and dulaglutide in T2D patients (Doggrell, 2023). Phase 3 trials are ongoing across multiple T2D populations, including one specifically studying participants with renal impairment (NCT06297603).

Fatty liver disease (MASLD/NASH). This is one of the most promising areas. The Phase 2b NASH results showing 73% resolution of disease (vs 18% placebo) are among the best numbers any drug has produced for this condition (Ciardullo et al., 2024). Current treatments for MASLD/NASH are limited, and this represents a genuine unmet medical need that retatrutide may help fill.

Osteoarthritis. The TRIUMPH Phase 3 trial specifically enrolled participants with obesity and cardiovascular disease. A notable secondary finding was "substantial relief from osteoarthritis pain." This tracks with what we know about mechanical load on joints. Losing 50+ pounds reduces joint stress dramatically. Whether there's a direct anti-inflammatory effect beyond the weight loss itself is still being studied.

Cardiovascular outcomes. The SELECT trial with semaglutide showed 20% reduction in cardiovascular events (MACE) in patients with established CVD (Lincoff et al., 2023). Retatrutide has its own cardiovascular outcomes trial running (1,800 patients, 113-week duration). Results will determine whether the glucagon agonism component adds, subtracts from, or has neutral effect on cardiovascular risk.

Cognitive and neurological effects. Drucker (2024) notes that GLP-1 trials are now testing efficacy in Parkinson's disease and Alzheimer's disease. Retatrutide's broader metabolic action makes it an interesting candidate for conditions where neuroinflammation and metabolic dysfunction intersect. This is early-stage research, not an established indication.

The picture emerging is a drug that doesn't just help people lose weight. It addresses the metabolic consequences of obesity at multiple levels simultaneously. Melson et al. (2024) summarized the pipeline perspective: retatrutide "may lead to even greater weight loss than tirzepatide" while sharing tirzepatide's cardiometabolic benefit profile.

---

The Retatrutide Trial Picture: Where Things Stand

There are currently multiple active trials testing retatrutide across different populations and indications.

TRIUMPH program (obesity): The main Phase 3 program. The headline result (28.7% weight loss at 68 weeks) came from the obesity with cardiovascular disease cohort (NCT05882045, n=1,800). This trial is still active, not yet complete for all endpoints.

Retatrutide vs Tirzepatide head-to-head: NCT06662383, 800 participants, ~89 weeks, directly comparing the two drugs on body weight and cardiometabolic outcomes. This is the trial the field is watching most closely. No results published as of April 2026.

Type 2 diabetes trials: Multiple Phase 3 studies across different T2D populations including renal impairment (NCT06297603) and cardiovascular disease co-occurring with T2D.

Hypoglycemia response (Phase 1): NCT06982846, studying counterregulatory response to low blood sugar in T2D patients on retatrutide, a safety question related to the glucagon component.

Community trial (Hudson Biotech): A Phase 2 study (NCT07467447, n=300) from a separate sponsor adding to the evidence base.

The TRIUMPH obesity trial primary completion date and the full Phase 3 cardiovascular outcomes data are the two pieces Eli Lilly needs for an FDA NDA submission. The 2027 approval timeline is the current consensus estimate from analysts covering the obesity drug pipeline (Madsbad & Holst, 2025).

---

Retatrutide vs Semaglutide: If You're Deciding Now

Most people reading about retatrutide are currently on semaglutide or considering it, and wondering whether to wait. Here's the honest comparison.

Semaglutide (Ozempic for T2D, Wegovy for weight management) is FDA-approved, widely available, has prescriber experience from years of use, and produces about 15% body weight reduction at 2.4 mg weekly.

Retatrutide produces roughly double those numbers, is not FDA-approved, cannot be legally prescribed, and has no compounding pathway. If you're seeing it offered by a clinic today, ask pointed questions about what exactly they're providing, from what source, and with what quality control.

The decision for most people right now comes down to: start an approved, available drug that works well, or wait for something better that isn't accessible yet. Your provider's job is to make that individualized assessment with you. There's no one-size answer.

If weight loss has plateaued on semaglutide, the current approved step-up is tirzepatide, which adds GIP agonism and consistently outperforms semaglutide in head-to-head data. Learn more about how semaglutide compares to tirzepatide in our GLP-1 Medications Compared guide.

---

Retatrutide Availability: How to Actually Get It Right Now

This is the question most people arrive at after reading the trial data. The honest answer has several parts.

You cannot get prescription retatrutide from a licensed US physician. It isn't FDA-approved. There is no NDA (New Drug Application) on file. No licensed compounding pharmacy has a legal basis to produce it because it doesn't appear on any FDA approved drug list or compounding-eligible substance list. Anyone offering it through a telehealth clinic with a legitimate prescription is misrepresenting what they're providing.

Clinical trials are the only legal access pathway. Eli Lilly is actively running Phase 3 trials. Some are still enrolling. To check eligibility, go to clinicaltrials.gov and search "retatrutide" to see current recruitment status for each study. The Hudson Biotech Phase 2 (NCT07467447) is recruiting 300 participants with obesity. Clinical trial participants receive the drug, monitoring, and labs at no cost, and they contribute to the data that will get this drug approved.

Gray-market research peptide sources exist. This is the uncomfortable reality. Vendors are selling retatrutide as a "research chemical" with disclaimers about it not being for human use. Some people in bodybuilding and biohacking communities are using it. The risks here are real: no pharmaceutical-grade quality control, no verified purity, no dosing accuracy, no physician monitoring for the adverse events that matter most (heart rate changes, GI complications, hypoglycemia in T2D patients). The community data, including compelling Reddit posts from people who lost 70+ pounds, is real. The risk from unverified sources is also real.

What it costs — if and when it's approved. Based on tirzepatide pricing as a precedent (Zepbound launched at around $1,100/month), expect retatrutide to launch in a similar or higher range. GLP-1 drugs remain expensive and frequently not covered by insurance for weight management specifically, though that's changing. Lilly Direct programs have offered tirzepatide for around $550/month directly, and a similar model for retatrutide is likely at launch.

What HEXIS can offer right now. Retatrutide isn't something we can prescribe. What we can do: evaluate whether tirzepatide or semaglutide is the right starting point for you based on your labs, health history, and goals. We can establish a protocol that positions you to transition to retatrutide through your prescribing provider once FDA approval comes through. Your protocol starts with labs, not guesswork.

If fatty liver disease is part of your picture, read our article on Fatty Liver and Weight Loss. GLP-1 treatment for MASLD is one area where current evidence is already strong and actionable.

---

Cost, Insurance, and Access — The Practical Picture

Until FDA approval, there's no legitimate cost structure for retatrutide as a prescription drug. But the pricing picture for approved drugs matters.

Semaglutide (Wegovy) for weight loss: Around $1,300-$1,600/month list price. Insurance coverage is inconsistent. Medicare now covers it; private insurers vary widely. Novo Nordisk offers a savings card for commercially insured patients that can reduce cost significantly.

Tirzepatide (Zepbound) for weight loss: Launched at around $1,100/month list. Lilly Direct offers self-pay pricing around $550/month. Coverage is expanding as obesity is increasingly recognized as a treatable disease, not a lifestyle choice.

Compounded semaglutide: During the shortage period, compounded versions were widely available. The FDA shortage list status changes, so check current compounding eligibility with your provider.

Clinical trial participation: Free access to retatrutide itself, plus monitoring. Eli Lilly's TRIUMPH trials are at major academic medical centers. Hudson Biotech's Phase 2 (NCT07467447) appears designed for broader geographic reach. This is the only legitimate access route before approval.

Post-approval projections: Industry analysts and researchers tracking the obesity drug pipeline (Bailey et al., 2025; Madsbad & Holst, 2025) consistently point to a 2027 earliest approval window. That assumes Phase 3 completion, FDA NDA submission, and standard review with no significant safety signals that would trigger a longer timeline.

At HEXIS, we work with patients to navigate GLP-1 access, including what programs exist, what the out-of-pocket picture looks like, and how to structure a protocol that makes financial sense. Schedule a consultation to start the conversation about retatrutide and where you stand today.

---

Frequently Asked Questions About Retatrutide

Is retatrutide FDA-approved?

No. As of April 2026, retatrutide remains investigational. Eli Lilly has Phase 3 trials active across obesity and type 2 diabetes populations. The earliest realistic FDA approval date is 2027, assuming successful Phase 3 completion and standard NDA review. No approved indication, no prescribing label, no licensed compounding pathway currently exists.

How does retatrutide compare to tirzepatide for weight loss?

Retatrutide has produced larger weight loss in trials (24.2% at 48 weeks in Phase 2 and 28.7% at 68 weeks in Phase 3) compared to tirzepatide's 22.5% at 72 weeks in SURMOUNT-1. A direct head-to-head Phase 3 trial (NCT06662383, n=800, ~89 weeks) is currently active. The mechanistic difference is the glucagon receptor. Retatrutide adds glucagon agonism to the GIP/GLP-1 combination, which appears to maintain metabolic rate and drive additional fat oxidation during weight loss.

What are the most common retatrutide side effects?

Nausea, diarrhea, vomiting, and constipation are the most frequently reported side effects, the same pattern seen across the GLP-1 drug class. Most side effects occur during dose escalation and improve at steady state. In the Phase 2 trial (Jastreboff et al., 2023), 19% of participants on 12 mg discontinued due to adverse events. Heart rate increase (up to 6.7 beats/min) is a class effect to discuss with your provider, especially if you have cardiac history.

Can I get retatrutide through a clinical trial?

Yes, this is currently the only legitimate access pathway. Eli Lilly's TRIUMPH program and the Hudson Biotech Phase 2 trial (NCT07467447) are recruiting. Search clinicaltrials.gov for current eligibility criteria and open recruitment sites. Clinical trial participants receive the study drug, monitoring, and labs at no cost. Enrollment criteria typically require a BMI above a specific threshold and absence of certain conditions.

How does retatrutide affect fatty liver disease?

The Phase 2b NASH data showed 86% of patients on retatrutide 8 mg achieved ≥50% liver fat reduction at 48 weeks, and 73% achieved NASH resolution without worsening fibrosis (Ciardullo et al., 2024). These are the best numbers any pharmaceutical intervention has produced for MASLD/NASH. The glucagon receptor component drives liver fat oxidation directly, making retatrutide potentially more effective for fatty liver than GLP-1 or GIP/GLP-1 drugs alone.

---

What to Do Right Now If Retatrutide Is On Your Radar

You've done your homework. You know what the trial numbers show. You want access to something that produces those kinds of results.

Here's the realistic path forward.

First, if you're not on any GLP-1 therapy, starting tirzepatide now is not a concession. It's a smart move. Tirzepatide produces 22.5% weight loss in clinical trials. That's real, accessible, and FDA-approved. Starting a physician-guided protocol that produces meaningful metabolic improvements while waiting for retatrutide to gain approval is better than waiting and losing nothing.

Second, if you have characteristics that make you an ideal trial candidate (BMI above 30, no current GLP-1 treatment, willing to commit to trial monitoring requirements), look at clinicaltrials.gov now. Enrollment windows close. Getting into a Phase 3 trial means you might get retatrutide before anyone else, at zero cost, with physician monitoring.

Third, be skeptical of gray-market sources. The community results are real and compelling. The source quality is not verifiable, the dosing is not reliable, and the risk of something going wrong without a physician monitoring your response is real. Physician oversight matters for a drug class that affects heart rate, gastric motility, and blood glucose regulation.

At HEXIS, your protocol starts with labs. We look at your current metabolic picture (fasting insulin, lipids, liver enzymes, HbA1c if indicated, and the full panel your regular doctor probably didn't run) and build from there. When retatrutide is approved and available, your provider can make an informed transition decision based on actual data, not guesswork.

Schedule a consultation and let's figure out where you stand right now.

---